PCA
RARE icon

Personal Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Personal Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,790
Closed -$266K – 215
2016
Q4 		$266K Buy
+3,790
New +$269K 0.01% 162

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Personal Capital Advisors's RARE Position: Q1 2017 in Review

Personal Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 3,790 shares — an estimated $266K sold.

Personal Capital Advisors first reported a position in RARE in Q4 2016 and held it in 1 quarter. The position peaked at $266K in Q4 2016. 164 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

  • Personal Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
  • Personal Capital Advisors sold 3,790 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $266K.
  • Personal Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 1 quarter.
  • Personal Capital Advisors's Ultragenyx Pharmaceutical position peaked at $266K in Q4 2016.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on Personal Capital Advisors's 13F filing for Q1 2017, filed 24 Apr 2017.